Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis-Reference-Cited by-同舟云学术

Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Published:2021-01 Issue:1 Volume:32 Page:2-12.e1
ISSN:1051-0443
Container-title:Journal of Vascular and Interventional Radiology
language:en
Short-container-title:Journal of Vascular and Interventional Radiology

Author:

Wu Xiao^ORCID,Chapiro Julius,Malhotra Ajay^ORCID,Kothary Nishita

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging

Reference26 articles.

1. AASLD guidelines for the treatment of hepatocellular carcinoma;Heimbach;Hepatology,2018

2. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma;Golfieri;Br J Cancer,2014

3. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria;Brown;J Vasc Interv Radiol,2009

4. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis;Facciorusso;Dig Liver Dis,2016

5. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival;Llovet;Hepatology,2003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stability of doxorubicin in radiocontrast medium for use in conventional transarterial chemo‐embolisation procedures;Journal of Medical Imaging and Radiation Oncology;2024-03-04

2. Research Consensus Panel Follow-Up: A Systematic Review and Update on Cost Research in IR;Journal of Vascular and Interventional Radiology;2023-07

3. Learning Visual Representations via Language-Guided Sampling;2023 IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR);2023-06

4. The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time;Hepatoma Research;2022

5. IR Liver-Directed Therapies for HCC;Hepato-Pancreato-Biliary Malignancies;2022